Evidence map›Paper›PMID 21285395›Full record

ArticleJournal of leukocyte biology2011

Alternatively spliced variants of interleukin-4 promote inflammation differentially.

Irina G Luzina, Virginia Lockatell, Nevins W Todd, Kendrick Highsmith, Achsah D Keegan, Jeffrey D Hasday, Sergei P Atamas

Abstract read
In one paragraph

Article in Journal of leukocyte biology, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed
1.3field-weighted citation impact, top 19% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

13 citing papers in PubMed, 28 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Interleukin-33 potentiates bleomycin-induced lung injury.American journal of respiratory cell and molecular biology · 2013
    Article
  9. Cytokines in chronic respiratory diseases.F1000 biology reports · 2013
    Article
  10. Review
  11. Article
  12. Article
  13. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 1 country.

Irina G LuzinaDepartment of Medicine, University of Maryland School of Medicine, Baltimore, Maryland 21201, USA.
Virginia Lockatell
Nevins W Todd
Kendrick Highsmith
Achsah D Keegan
Jeffrey D Hasday
Sergei P Atamas
University of Maryland, Baltimore · USBaltimore VA Medical Center · US

Funding

Molecular Mechanisms of IL-4 and IL-13 SignalingR01AI038985 · NIAID · UNIVERSITY OF MARYLAND BALTIMORE · PI KEEGAN, ACHSAH D. · 2001 to 2010
$3.7M
NIAID NIH HHS R01 AI038985
6 · The paper itself

Abstract

IL-4δ2 is a natural splice variant of IL-4 that lacks the region encoded by the second exon. Numerous reports have suggested that the expression levels of IL-4δ2 change in various diseases, especially those with pulmonary involvement, but the in vivo effects of this splice variant have never been studied. Replication-deficient, AdV-mediated gene delivery of mIL-4δ2 to mouse lungs in vivo was used, and the effects compared with similar adenoviral delivery of mIL-4 or with infection with a noncoding NULL viral construct. Overexpression of IL-4δ2 or IL-4 caused pulmonary infiltration by T and B lymphocytes, whereas in contrast to IL-4, IL-4δ2 did not induce eosinophilia or goblet cell hyperplasia. Microarray analysis of global gene expression revealed that IL-4δ2 and IL-4 had differential effects on gene expression. These splice variants also differentially regulated pulmonary levels of the cytokines TNF-α, eotaxin, IL-1α, IFN-γ, and MCP-1, whereas both tended to increase total lung collagen modestly. Pulmonary infiltration by lymphocytes in response to overexpression of IL-4δ2 was attenuated but not abrogated completely by germline deficiency of IL-4Rα or STAT6, whereas deficiency of endogenous IL-4 had no effect. Thus, IL-4δ2 promotes lymphocytic inflammation in vivo (although differentially from IL-4, in part), and the effects of IL-4δ2 are not mediated by endogenous IL-4. Differential targeting of IL-4δ2 and IL-4 may therefore be considered in developing future therapeutic agents.

Indexed as

Alternative SplicingAdenoviridaeAnimalsCells, CulturedCollagenCytokinesDisease Models, AnimalFlow CytometryGenetic TherapyGene Transfer TechniquesGoblet CellsInflammationInterleukin-4Interleukin-4 Receptor alpha SubunitLung DiseasesMiceCollagenCytokinesIl4ra protein, mouseInterleukin-4Interleukin-4 Receptor alpha SubunitReceptors, Cell SurfaceStat6 protein, mouseSTAT6 Transcription Factor

Identifiers

PMID21285395
PMCPMC6608013
OpenAlexW2136449357

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.